Compare MOLN & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOLN | SMTI |
|---|---|---|
| Founded | 2004 | 1982 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.9M | 182.6M |
| IPO Year | 2021 | 2008 |
| Metric | MOLN | SMTI |
|---|---|---|
| Price | $4.26 | $18.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $8.38 | ★ $41.00 |
| AVG Volume (30 Days) | 3.9K | ★ 52.8K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,586,976.00 |
| Revenue This Year | N/A | $20.66 |
| Revenue Next Year | $318.52 | $13.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.47 |
| 52 Week Low | $3.36 | $18.29 |
| 52 Week High | $5.36 | $35.70 |
| Indicator | MOLN | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 40.95 |
| Support Level | $3.51 | $18.60 |
| Resistance Level | $4.63 | $21.14 |
| Average True Range (ATR) | 0.28 | 0.99 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 34.92 | 7.63 |
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.